ABL1 and Parkinson disease: Inhibitors of c-Abl have the ability to cross the BBB and provide protective action against toxicity, induced by MPTP in mouse model of PD, by reversing the loss of dopaminergic neurons with noticeable improvement in motor symptoms [185].